3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
16
Stomach Neoplasms
7
Melanoma
7
Rectal Neoplasms
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Hepatocellular
6
Neoplasms
5
Neoplasm Metastasis
5
Esophageal Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Colonic Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Gastrointestinal Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Renal Cell
3
Carcinoma, Merkel Cell
3
Anus Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Interventions
pembrolizumab
2
fludarabine
2
aldesleukin
2
Riluzole
2
Genetic Testing
2
Cyclophosphamide
2
motexafin gadolinium
1
lenvatinib
1
atezolizumab
1
Tinzaparin
1
Specimen Handling
1
Sildenafil Citrate
1
Remote Patient Monitoring
1
National Cancer Institute (U.S.)
1
Interleukin-2
1
Genetic Counseling
1
Fatty Acids, Omega-3
1
Doxorubicin
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Interleukin-2
×
Gastrointestinal
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled